KMPH Projected Dividend Yield

KemPharm Inc ( NASDAQ : KMPH )

KemPharm is a specialty pharmaceutical company focused on the discovery and development of treatments for central nervous system (CNS) and rare disease indications that allow it to target areas with unmet needs. Co.'s prodrug product candidate pipeline is focused on the idiopathic hypersomnia (IH) and other CNS/rare diseases. Co.'s approved product, AZSTARYS®, a once-daily treatment for attention deficit hyperactivity disorder in patients, age six years and older, contains its prodrug, serdexmethylphenidate (SDX). Co.'s primary clinical development product candidate, KP1077, is based on SDX, its prodrug of d-methlyphenidate and is in development for the treatment of IH and narcolepsy.

20 YEAR PERFORMANCE RESULTS